公开(公告)号：US20170137485A1

公开(公告)日：2017-05-18

申请号：US15408281

申请日：2017-01-17

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55

CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US20140286898A1

公开(公告)日：2014-09-25

申请号：US14209699

申请日：2014-03-13

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/18

CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US20180319859A1

公开(公告)日：2018-11-08

申请号：US15901705

申请日：2018-02-21

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/00 ,  A61K38/00

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

公开(公告)号：US20140343252A1

公开(公告)日：2014-11-20

申请号：US14209914

申请日：2014-03-13

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/00

CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。